Abstract:Introduction Epidermal growth factor receptor 2 (HER2)-targeted therapies are effective treatments for HER2+ breast cancers (BC), but intrinsic and acquired resistance hampers their clinical benefit. Therefore, new biological insights into HER2-driven cancers are needed to conquer drug resistance. Here, we used a genetically diverse and population-based Collaborative Cross (CC) mouse model to identify genetic susceptibility to tumor development and metastasis driven by HER2. Materials and methods 732 F1 hybrid mice were generated from a cross between FVB/N MMTV-ErbB2 and 30 CC strains and were monitored for mammary tumor development within two years. Tumor onset, multiplicity and metastasis were assessed. Genome wide association study (GWAS) was used to identify genetic variations controlling different tumor phenotypes. Polygenetic risk score was created for each phenotype using multivariate analysis. We systematically evaluated the clinical value regarding prognosis and therapeutic responses of mouse tumor susceptibility gene signature (mTSGS) in human breast cancer (BC) using publicly available cohorts including I-SPY2 clinical trial cohorts. Results We observed huge differences in tumor onset, multiplicities, and metastasis across 30 CC strains. In addition to lung metastasis, we found liver/kidney metastasis in some CC strains. GWAS identified 1,525 SNPs significantly associated with tumor onset (p<1.00E-30) corresponding to 287 known genes, 800 SNPs significantly associated with number of tumors (p<1.00E-15) corresponding to 203 known genes, 568 SNPs significantly associated with lung metastasis (p<1.00E-4) corresponding to 189 known genes, and 23 SNPs significantly associated with liver metastasis (p<1.00E-4) corresponding to 12 known genes. Multivariate analyses identified the SNPs in 8 genes (Stx6, Ramp1, Traf3ip1, Nckap5, Pfkfb2, Trmt1l, Rprd1b and Rer1) independently associated with age onset, in 11 genes (Stx6, Sepsecs, Rhobtb1, Tsen15, Abcc3, Arid5b, Tnr, Dock2, Tti1, Fam81a and Oxr1) independently associated with number of tumors, and in 2 genes (Plxna2 and Tbc1d31) independently associated with tumor metastasis, which were pooled together as mTSGS. To evaluate the impact of mTSGS on human BC, we established mTSGS score (mTSGSS) based on their transcriptional levels in BC. We found that mTSGSS is significantly and independently associated with overall, disease free and progression free survival compared to clinical factors and PAM50 molecular subtype in different cohorts. Additionally, patients with low mTSGSS have a higher pathological complete response (pCR) rate in comparison to these with high mTSGSS for 6 of 13 treatment regimens in I-SPY2 cohort. Multivariate logistic regression analysis showed that predictive value of mTSGSS in pCR is independent of MammaPrint (MP) score in these treatment regimens. Conclusion Our findings lead significantly to biological insights into ErbB2-driven cancers and indicate that mTSGSS can serve as a biomarker for tailoring treatment to BC patients. Citation Format: Hang Chang, Jamie L Inman, Antoine M Snijders, Jian-Hua Mao. Identification of genetic susceptibility loci for ErbB2-driven mammary tumor development and metastasis using Collaborative Cross mice and human relevant validation [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr A004.

From Mouse to Human: Cellular Morphometric Subtype Learned from Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer.

Abstract 5622: Integrative cross-platform characterisation of mammographic screen-detected breast cancer

Conserved Genetic Networks Define Er-Alpha Status And Luminal And Basal Phenotypes In Mouse And Human Mammary Cancer: Added Value From The Mouse

Transposon Insertional Mutagenesis In Mice Identifies Human Breast Cancer Susceptibility Genes And Signatures For Stratification

Human Mammary Microenvironment Better Regulates the Biology of Human Breast Cancer in Humanized Mouse Model

Mouse models of breast cancer in preclinical research

Integrated Mirna and Mrna Expression Profiling of Mouse Mammary Tumor Models Identifies Mirna Signatures Associated with Mammary Tumor Lineage

Pixel-Level Clustering of Hematoxylin-Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer

Human Tissue-Specific Microenvironment: an Essential Requirement for Mouse Models of Breast Cancer.

Global Expression Profiling and Pathway Analysis of Mouse Mammary Tumor Reveals Strain and Stage Specific Dysregulated Pathways in Breast Cancer Progression.

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy

A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer

Abstract A004: Identification of genetic susceptibility loci for ErbB2-driven mammary tumor development and metastasis using Collaborative Cross mice and human relevant validation

MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer

Identification of Differentially Expressed Genes Between Original Breast Cancer and Xenograft Using Machine Learning Algorithms

Quantitative diagnosis of breast tumors by morphometric classification of microenvironmental myoepithelial cells using a machine learning approach

Abstract 2839: The mouse models of human cancer database (MMHCdb)

Exploration of a noninvasive radiomics classifier for breast cancer tumor microenvironment categorization and prognostic outcome prediction

Deep-learning and transfer learning identify new breast cancer survival subtypes from single-cell imaging data

An AI-Powered tissue-agnostic cellular morphometrics biomarker for risk assessment in patients with pan-gastrointestinal precancerous lesions and cancers

Quantitative MRI Radiomics in the Prediction of Molecular Classifications of Breast Cancer Subtypes in the TCGA/TCIA Data Set